TICKERNERD
Menu
VCYTVCYTHealthcare · Diagnostics & Research

VCYT Stock Forecast: Veracyte, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$41
−3.17% on the day

The 12 Wall Street analysts covering Veracyte, Inc. hold a median 12-month price target of $55 — +33.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$3.3B
Ticker Nerd rank
97 / 100
Median analyst target
$55
Analysts covering
12
Total return, dividends reinvested
1W
−12.6%
1M
−27.1%
YTD
−2.0%
1Y
+37.3%
From 52W high
−31.8%
From 52W low
+44.2%
$29
$60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VCYT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Veracyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
97 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
91
Quality
90
Revisions
85
Growth
83
Volatility
70
Momentum
70
Issuance
64
Accruals
64
Size
30

Value (91): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (64): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (30): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VCYT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VCYT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26VCYTHigh $70Median $55Low $44

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says12 analysts
10 Buy1 Hold1 Sell
Low $44Median $55High $70

The green dot is the last close — the median target sits +33.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
4 Aug 2026Morgan StanleyMaintainsUnderweight$47 → $44
4 Aug 2026Piper SandlerMaintainsOverweight$66 → $54
4 Aug 2026Stephens & Co.MaintainsOverweight$68 → $55
3 Aug 2026Canaccord GenuityMaintainsHold$60 → $50
31 July 2026NeedhamMaintainsBuy$57 → $69
30 July 2026NeedhamMaintainsBuy$57 → $69
15 July 2026Piper SandlerInitiatesOverweight$66
15 July 2026Piper SandlerInitiatesOverweight—
14 July 2026Canaccord GenuityMaintainsHold$42 → $60
14 July 2026Canaccord GenuityMaintainsHold—
9 July 2026Morgan StanleyMaintainsUnderweight$37 → $47
9 July 2026Morgan StanleyMaintainsUnderweight—
29 June 2026GuggenheimMaintainsBuy—
1 June 2026NeedhamMaintainsBuy—
28 May 2026NeedhamReiteratesBuy—
6 May 2026Canaccord GenuityMaintainsHold—
6 May 2026UBSMaintainsBuy—
20 Apr 2026Canaccord GenuityMaintainsHold—
13 Apr 2026JefferiesInitiatesBuy—
1 Apr 2026NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VCYT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

VCYT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+15.7%
Analysts raising
1
Analysts cutting
1
Fundamentals

Veracyte, Inc. (VCYT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
29.5×

Cheaper than 28% of US stocks

Price / sales
5.9×

Cheaper than 22% of US stocks

Price / book
2.5×

Cheaper than 40% of US stocks

EV / EBITDA
26.2×

Cheaper than 11% of US stocks

Growth & margins
Revenue growth (YoY)
15.5%

Higher than 63% of US stocks

Earnings growth (YoY)
15.5%

Higher than 54% of US stocks

Gross margin
72.2%

Higher than 85% of US stocks

Operating margin
15.3%

Higher than 73% of US stocks

Net margin
20.4%

Higher than 83% of US stocks

Returns & dividend
Return on equity
8.8%

Higher than 61% of US stocks

Return on assets
4.1%

Higher than 71% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VCYT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
VCYTVeracyte, Inc.$3.3B
97
GRALGRAIL, Inc.$3.0B
36
ADPTAdaptive Biotechnologies Corp.$4.0B
78
BLLNBillionToOne, Inc.$4.4B
15
CDNACareDx, Inc.$2.3B
100
WGSGeneDx Holdings Corp.$2.2B
47
NEONeoGenomics, Inc.$2.0B
76

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Veracyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VCYT news & analysis

Veracyte: Diagnostics With Favorable Economics

Seeking Alpha · 10 Aug 2026positive

Seeking Alpha highlights that Veracyte's core Decipher and Afirma tests are generating double-digit growth with improving margins, positioning the company as a potential long-term cash flow machine. The piece also notes that Prosigna and TrueMRD present additional upside not yet reflected in management's 2026 testing-revenue guidance.

Why it matters — VCYT watchers would care because sustained double-digit growth and margin improvement in the core test portfolio, plus unguided upside from Prosigna and TrueMRD, point to a strengthening revenue and cash flow trajectory.

Veracyte: Core Growth Funds Prosigna And TrueMRD

Seeking Alpha · 10 Aug 2026positive

Veracyte is described as evolving into a self-funded cancer diagnostic platform. Q2 2026 results showed 15% revenue growth, 23% adjusted EBITDA growth, and a 29.2% EBITDA margin, with robust cash generation and no funded debt; Prosigna and TrueMRD launches are excluded from 2026 guidance while Decipher and Afirma drive core growth.

Why it matters — The item highlights that Prosigna and TrueMRD represent potential upside beyond current guidance while core products drive margin expansion, giving VCYT watchers insight into the company's growth and financial trajectory.

Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 31 July 2026neutral

Veracyte, Inc. published its Q2 2026 earnings call transcript on Seeking Alpha.

Why it matters — Earnings call transcripts offer investors direct insight into Veracyte's quarterly financial results and management's commentary on the business.

Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates

Zacks Investment Research · 30 July 2026positive

Veracyte reported Q2 earnings of $0.54 per share, surpassing the Zacks Consensus Estimate of $0.43 per share and up from $0.44 per share in the same quarter last year.

Why it matters — The better-than-expected quarterly results indicate that Veracyte's earnings performance exceeded analyst forecasts and improved year-over-year.

Veracyte Announces Second Quarter 2026 Financial Results

GlobeNewsWire · 30 July 2026positive

Veracyte reported second quarter 2026 financial results, with total revenue reaching $150.3 million and testing revenue of $145.7 million, representing year-over-year increases of 15% and 19%, respectively.

Why it matters — The double-digit revenue growth, particularly in testing revenue, signals continued strong demand for Veracyte's diagnostic tests.

FAQ

Frequently asked questions about VCYT stock

What is the VCYT stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Veracyte, Inc. have a median 12-month price target of $55, with estimates ranging from $44 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VCYT stock a buy right now?

Of the 12 analysts covering Veracyte, Inc., 10 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Veracyte, Inc. 97 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VCYT?

As at 15 Aug 2026, Veracyte, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (91 of 100).

Will VCYT stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +33.3% from the last close, and Ticker Nerd's factor model ranks Veracyte, Inc. 97 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VCYT stock forecast for 2030?

No analyst covering Veracyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VCYT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $70 over the next 12 months.

How has VCYT stock performed over the past year?

Veracyte, Inc. returned +37.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Veracyte, Inc. do?

Veracyte Inc. is a global diagnostics company specializing in advanced genomic tests that provide clinicians with precise insights to diagnose and treat cancer.

What is the latest news on VCYT?

The most recent item we track (Seeking Alpha, 10 Aug 2026): "Veracyte: Diagnostics With Favorable Economics". Seeking Alpha highlights that Veracyte's core Decipher and Afirma tests are generating double-digit growth with improving margins, positioning the company as a potential long-term cash flow machine. The piece also notes that Prosigna and TrueMRD present additional upside not yet reflected in management's 2026 testing-revenue guidance.

Company

About Veracyte, Inc.

Veracyte Inc. is a global diagnostics company specializing in advanced genomic tests that provide clinicians with precise insights to diagnose and treat cancer. Its portfolio features key products such as Afirma for thyroid cancer, Decipher Prostate and Decipher Bladder for prostate and bladder cancers respectively, Prosigna for breast cancer, Envisia for interstitial lung diseases including idiopathic pulmonary fibrosis, and Percepta for lung cancer diagnosis. These molecular diagnostics leverage genomic sequencing, machine learning, and clinical data through the company's innovative Veracyte Diagnostics Platform, enabling AI-assisted analysis and evidence generation to support personalized treatment decisions and avoid unnecessary surgeries. Veracyte Inc. operates centralized CLIA labs in the US and offers distributed in vitro diagnostics for international markets across North America, Europe, and the Middle East, serving healthcare providers, biopharmaceutical partners, and biotechnology sectors. Founded in 2006 and headquartered in South San Francisco, California, the company plays a vital role in precision oncology by transforming cancer care with actionable genomic information at critical decision points.

CEO Mr. Marc A. Stapley · 755 employees · United States · https://www.veracyte.com